Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• Atherosclerosis is the primary cause of cardiovascular disease.
• Low-density lipoprotein cholesterol is a key risk factor for atherosclerosis.
• Epidemiologic data and clinical trials link lower cholesterol to reduced coronary heart disease risk.

Purpose of the Study:

• To evaluate the impact of aggressive cholesterol reduction on clinical outcomes.
• To assess the benefits of HMG-CoA reductase inhibitors (statins) in managing atherosclerosis.
• To explore the potential reclassification of lipid-lowering drugs as anti-atherosclerotic agents.

Main Methods:

• Review of epidemiologic studies on cholesterol levels and cardiovascular risk.
• Analysis of data from clinical trials involving lipid-lowering agents, particularly statins.
• Examination of evidence from recent trials like Atorvastatin Versus Revascularization Treatment.

Main Results:

• Statins demonstrate significant lipid-lowering effects.
• Aggressive cholesterol reduction provides clinical benefits beyond less intensive regimens.
• Lowering cholesterol is associated with reduced morbidity and mortality from coronary heart disease.

Conclusions:

• Aggressive cholesterol-lowering strategies can substantially impact atherosclerosis prevalence.
• The evidence supports considering statins as anti-atherosclerotic agents rather than solely lipid-lowering drugs.
• These findings have significant implications for managing cardiovascular disease globally.